Quantcast

Latest neutropenia Stories

2010-10-26 13:57:00

PALO ALTO, Calif., Oct. 26 /PRNewswire/ -- Telik, Inc.

2010-10-01 07:00:00

BRIDGEWATER, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S.

2010-09-26 16:00:00

MELBOURNE, Australia, Sept. 26 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that it has received Australian Therapeutic Goods Administration (TGA) approval for its biosimilar filgrastim product, Nivestim(TM).

2010-08-05 07:00:00

BRIDGEWATER, N.J., Aug. 5 /PRNewswire/ -- Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate.

2010-06-17 14:40:00

PARIS, June 17 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S.

2010-06-10 08:45:00

LEAMINGTON SPA, United Kingdom, June 10 /PRNewswire-FirstCall/ -- Hospira announced today that the EC has approved Nivestim(TM) (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy(1).

2010-06-06 11:30:00

CHICAGO, June 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

2010-03-11 22:00:00

WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ -- Eisai Inc. today announced that the U.S.

2010-03-10 12:13:34

Multicenter trial led by St Jude Children's Research Hospital investigators may change neutropenia treatment for all childhood cancer patients.


Word of the Day
swell-mobsman
  • A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.
Use of the word 'swell-mobsman' dates at least to the early 1800s.